Incretins: all 1,182 studies that test it

Page 10 of 12. Open to participants first (46), then studies with results posted, then the rest; newest registration first within each.

• Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA)CompletedNCT02043054Phase 3
• Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical TreatmentCompletedNCT02041234Phase 4
• Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes MellitusCompletedNCT02036372Not applicable
• Liraglutide Efficacy on Glucocorticoid Induced Hyperglycemia in Patients High Risk for DiabetesStatus unknownNCT02016846Phase 3
• Off taRget Effects of Linagliptin monothErapy on Arterial Stiffness in Early DiabetesCompletedNCT02015299Phase 3
• Efficacy Study of Glucagonlike Peptide-1 to Treat Reperfusion InjuryStatus unknownNCT02001363Not applicable
• Trial of Exenatide for Parkinson's DiseaseCompletedNCT01971242Phase 2
• Exenatide for Stress HyperglycemiaCompletedNCT01969149Phase 2/3
• Effect of Saxagliptin on Pre-Diabetes Mellitus and ObesityStatus unknownNCT01960205Phase 4
• Umbilical Cord Mesenchymal Stem Cells and Liraglutide in Diabetes MellitusStatus unknownNCT01954147Phase 1/2
• The Role of Cholinergic Signaling for Mediating the Effects of GIP and/or Xenin-25 on Insulin SecretionCompletedNCT01951729Phase 1
• Linagliptin in Schizophrenia PatientsTerminatedNCT01943019Phase 1
• Exenatide for Myocardial Protection During Reperfusion StudyStatus unknownNCT01938235Phase 2
• A Study to Investigate the Glucose Lowering Effects of Dextromethorphan Alone or in Combination With Sitagliptin in Subjects With Type 2 Diabetes Mellitus (T2DM) After an Oral Glucose Tolerance TestCompletedNCT01936025Phase 2
• Effect of Glucagon-like Peptide 1 (GLP-1) on Microvascular Myocardial Function in Patients With Type 2 Diabetes.CompletedNCT01931982Phase 4
• DPP4inhibitors in Type 1 DiabetesCompletedNCT01922817Phase 3
• A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy SubjectsCompletedNCT01916174Phase 1
• Polycystic Ovary Syndrome and Liraglutide as Add-on Therapy on MetforminCompletedNCT01911468Phase 4
• Effects of Linagliptin on Active GLP-1 Concentrations in Subjects With Renal ImpairmentCompletedNCT01903070Phase 4
• Effect of the DPP-4 Inhibitor Sitagliptin on Islet Function After Mixed Meal in Patients With Type 2 DiabetesCompletedNCT01901861Not applicable
• Polycystic Ovary Syndrome and LiraglutideCompletedNCT01899430Phase 4
• Triple Therapy in Type 2 Diabetic PatientsStatus unknownNCT01895569Phase 4
• Effects of Gemigliptin Versus Sitagliptin or Glimepiride With Metformin on Glucose Variability(MAGE, Glucose SD) Patients With Type 2 DM(STABLE Study)CompletedNCT01890629Phase 4
• Diastolic Dysfunction in Patients With Type 2 Diabetes MellitusTerminatedNCT01888796Phase 3
• Liraglutide in Newly Onset Type 1 Diabetes.CompletedNCT01879917Phase 2/3
• An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes MellitusCompletedNCT01876849Phase 3
• Bioequivalence StudyCompletedNCT01874080Phase 1
• Sitagliptin Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery DiseaseCompletedNCT01863147Phase 4
• GLP-1 and HypoglycemiaActive, not recruitingNCT01858896Early Phase 1
• Feasibility Study of Exenatide by Continuous Subcutaneous InfusionCompletedNCT01857895Phase 1
• Study of the Acute Metabolic Effect of Exenatide in Type 1 DiabetesCompletedNCT01855490Phase 1
• MASTERMIND - Understanding Individual Variation in Treatment Response in Type 2 DiabetesCompletedNCT01847144Phase 4
• Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients?Status unknownNCT01845259Phase 2
• A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.CompletedNCT01843127Phase 1
• Evaluating Liraglutide in Alzheimer's DiseaseStatus unknownNCT01843075Phase 2
• Effects of Linagliptin on Renal Endothelium Function in Patients With Type 2 Diabetes.CompletedNCT01835678Phase 3
• Exenatide on GI Motor Function and Permeability in Short Bowel SyndromeWithdrawnNCT01818648Phase 4
• The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced DiabetesCompletedNCT01795248Phase 4
• Incretin Regulation of Insulin Secretion in Monogenic DiabetesCompletedNCT01795144Phase 1
• Treatment of Antipsychotic-associated Obesity With a GLP-1 AnalogueCompletedNCT01794429Phase 3
• Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell FunctionStatus unknownNCT01790308Phase 4
• Extension Study for 2993-112CompletedNCT01789957Phase 3
• A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Liraglutide in Obese Adolescent Subjects Aged 12 to 17 YearsCompletedNCT01789086Phase 1
• A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1cTerminatedNCT01785771Phase 3
• Differences in Endothelial Function Amongst Sitagliptin and Liraglutide UsersCompletedNCT01785043Phase 4
• Effects of Exenatide on Obesity and/or Diabetes Mellitus Due to Hypothalamic DamageStatus unknownNCT01783717Not applicable
• Incretin Effect on the Immunological PhenotypeCompletedNCT01782261Phase 2
• Effect of Short-Term Intensive Insulin Sequential Exenatide Therapy in Newly Diagnosed Type 2 Diabetic PatientsCompletedNCT01776788Phase 4
• Metabolomic Variations in the Saxagliptin-Treated Type 2 Diabetes Mellitus PatientsStatus unknownNCT01768208Phase 4
• Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 PatientsCompletedNCT01761318Phase 4
• Effect of GLP-1 on Postprandial Lipid MetabolismStatus unknownNCT01760772Not applicable
• Blood Pressure Outcomes With Liraglutide TherapyCompletedNCT01755572Phase 4
• Hyperglycemia and the Extra-pancreatic Effect of IncretinsCompletedNCT01749163Not applicable
• SAFEGUARD: Pleiotropic Effects of Incretin Based TherapiesCompletedNCT01744236Phase 4
• Sitagliptin in Type I Diabetic PatientsWithdrawnNCT01741103Not applicable
• GLP-1 and Microvascular Function in Type 2 DiabetesCompletedNCT01740921Not applicable
• Influence of Appetite Related Hormones in Binge Eating Behaviour Among the Overweight and ObeseCompletedNCT01739049Phase 4
• Anti-diabetic Effects of Liraglutide in Adolescents and Young Subjects With Type 1 DiabetesWithdrawnNCT01722227Phase 3
• Treatment of Dysglycemia Using Sitagliptin in Adolescents With Cystic FibrosisCompletedNCT01721382Phase 1
• A Pilot Study to Assess the Glucose Lowering Effect of Metformin and Sitagliptin in Adolescents With Type 1 DiabetesCompletedNCT01718093Phase 4
• ß-Cell Function and Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients With Moderate HyperglycemiaStatus unknownNCT01717911Phase 4
• Efficacy and Safety Comparative Study of Sitagliptin,Vildagliptin and SaxagliptinStatus unknownNCT01703637Not applicable
• The Influence of Liraglutide on the Reward Properties of Food: an fMRI Study on Healthy VolunteersCompletedNCT01695109Phase 4
• The Microvascular Function of GLP-1 and Its AnaloguesCompletedNCT01677104Not applicable
• Effects of Liraglutide on Kidney Function in Type 2 Diabetic PatientsCompletedNCT01664676Phase 4
• Study of Comparing the Different Effect of DPP-4 Inhibitors and Sulfonylurea by Using "Biphase-Hyperglycemic Clamp"Status unknownNCT01660386Phase 4
• Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DMCompletedNCT01658501Phase 2
• Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II DiabeticsCompletedNCT01654120Phase 4
• Treatment With Sitagliptin in Non-obese Japanese Patients With Type 2 Diabetes MellitusStatus unknownNCT01642108Not applicable
• Study of Liraglutide in Individuals With Type 2 Diabetes Using InsulinTerminatedNCT01628445Phase 3
• Comparison of Hypoglycaemic Regimens During Ramadan Fasting in Type 2 DiabetesCompletedNCT01624116Not applicable
• Safety and Tolerability of Liraglutide in Healthy Japanese VolunteersCompletedNCT01620476Phase 1
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Healthy Japanese VolunteersCompletedNCT01620463Phase 1
• Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763CompletedNCT01619332Phase 1/2
• Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 DiabetesCompletedNCT01617824Phase 4
• Safety and Tolerability of Liraglutide in Japanese Subjects With Type 2 DiabetesCompletedNCT01615978Phase 1
• Liraglutide in Type 1 DiabetesCompletedNCT01612468Phase 4
• The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY)CompletedNCT01610934Phase 2/3
• Impact of Liraglutide on Sensory Perception, Sensory Specific Satiety, Liking and Wanting in Type 2 Diabetic PatientsCompletedNCT01599338Not applicable
• Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric BandingTerminatedNCT01597531Phase 4
• The Effect of Liraglutide on the Treatment of Coronary Artery Disease and Type 2 DiabetesCompletedNCT01595789Phase 4
• A Long-term Trial to Compare the Effects of Liraglutide and Sulphonylurea (Glimepiride) Both in Combination With Metformin on Clinical, Endothelial and Image Markers of Cardiovascular Risk in Patients With Type 2 DiabetesWithdrawnNCT01593137Phase 4
• GLP-1 Analogue Treatment in Uncontrolled Type 1 Diabetic PatientsStatus unknownNCT01592279Phase 4
• DIabetes REsearCh on Patient sTratification (DIRECT): GLP-1R AgonistsCompletedNCT01575301Not applicable
• Pharmacology of Exenatide in Pediatric SepsisWithdrawnNCT01573806Phase 1/2
• A Pilot Study Evaluating Safety of Sitagliptin Combined With Peg-IFN Alfa-2a + Ribavirin in Chronic Hepatitis C PatientsTerminatedNCT01567540Phase 1
• Saxagliptin and AtherosclerosisCompletedNCT01552018Phase 4
• Liraglutide Effects on Memory in Healthy SubjectsCompletedNCT01550653Phase 1
• Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes MellitusStatus unknownNCT01547104Phase 4
• Liraglutide Use in Prader-Willi SyndromeTerminatedNCT01542242Phase 4
• The Effect of Liraglutide Adjunct to Insulin on Glucagon Response to Hypoglycaemia in Subjects With Type 1 DiabetesCompletedNCT01536665Phase 1
• Effects of DPP-4 Inhibition on TriglyceridesSuspendedNCT01527747Phase 4
• Study of Combination Therapy With SYR-322CompletedNCT01521962Phase 3
• ACute and Chronic Effects of SaxagliptinCompletedNCT01521312Phase 2
• Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pHCompletedNCT01518166Phase 1
• Vildagliptin Versus Liraglutide - Patient Preference After Receiving Both MedicationsCompletedNCT01518101Phase 4
• Metabolism and Excretion of Liraglutide in Healthy Male VolunteersCompletedNCT01517568Phase 1
• Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 DiabetesCompletedNCT01517555Phase 1
• MK-0431/ONO-5435 Phase III Clinical Trial-Rapid-acting Insulin Secretagogue Add-on Study in Patients With Type 2 DiabetesCompletedNCT01517321Phase 3
• Study of RO6807952 in Patients With Diabetes Mellitus Type 2TerminatedNCT01516476Phase 2

← Incretins overview